• PDF / 169,712 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 104 Downloads / 174 Views

DOWNLOAD

REPORT

---

1 S

Cardiovascular and atherothrombotic toxicities: 25 case reports In a single-centre retrospective study involving 43 patients, 25 patients (7 women and 18 men) aged 23–79 years were described, who developed acute myocardial infarction (STEMI), acute arterial occlusion, arrhythmia, ischaemic stroke, pulmonary hypertension, pleural effusion, pericardial effusion, congestive heart failure, dyspnoea or hypertension during treatment with dasatinib, imatinib or nilotinib for chronic myeloid leukaemia [routes not stated; not all outcomes stated]. The patients with chronic myeloid leukaemia, started receiving treatments with dasatinib 100mg once daily (5 patients), imatinib 400mg once daily (11 patients), nilotinib 400mg twice daily (6 patients) and nilotinib 300mg twice daily (3 patients). However, within 18–114 months, the patients developed STEMI (2 patients), acute arterial occlusion (1 patient), arrhythmia (1 patient), ischaemic stroke (1 patient), congestive heart failure (2 patients), hypertension (5 patients), hypertension and small pericardial effusion (1 patient), STEMI, pulmonary hypertension, pleural effusion, pericardial effusion congestive heart failure, dyspnoea and hypertension (1 patient), pulmonary hypertension, pleural effusion and pericardial effusion (1 patient), congestive heart failure and hypertension (1 patient), and small pericardial effusion (9 patients). Therefore, the treatments with dasatinib (1 patient) and nilotinib (3 patient) were discontinued. The STEMI resolved in 1 patient. Varga A, et al. Cardiovascular events throughout the disease course in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors-A single-centre retrospective 803520639 study. Journal of Clinical Medicine 9: 1-14, No. 10, Oct 2020. Available from: URL: http://doi.org/10.3390/jcm9103269

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834